menu
    • menu
    [{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"RNA based therapies","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Versameb","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Undisclosed"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Touchlight"},{"orgOrder":0,"company":"Versameb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Inapplicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versameb \/ Versameb","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Versameb"}]

    Find Clinical Drug Pipeline Developments & Deals by Versameb

    Menu

    Versameb

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VMB-100

    Therapeutic Area : Urology

    Study Phase : Preclinical

    Sponsor : Touchlight

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Touchlight’s Enzymatic Doggybone DNA used in the Manufacture of Versameb’s VMB-100 for First-in-human Clin...

    Details : VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).

    Product Name : VMB-100

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    November 21, 2023

    Lead Product(s) : VMB-100

    Therapeutic Area : Urology

    Highest Development Status : Preclinical

    Sponsor : Touchlight

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VMB-100

    Therapeutic Area : Urology

    Study Phase : Preclinical

    Recipient : Touchlight

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Touchlight and Versameb Announce GMP Manufacturing Supply Agreement

    Details : The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.

    Product Name : VMB-100

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    March 01, 2022

    Lead Product(s) : VMB-100

    Therapeutic Area : Urology

    Highest Development Status : Preclinical

    Recipient : Touchlight

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VMB-100

    Therapeutic Area : Urology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Versameb to Present Novel Data on Its Lead Asset, VMB-100 at 9th International mRNA Health Conference

    Details : VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress U...

    Product Name : VMB-100

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    November 04, 2021

    Lead Product(s) : VMB-100

    Therapeutic Area : Urology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed

    Versameb

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RNA based therapies

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Study Phase : Preclinical

    Sponsor : Undisclosed

    Deal Size : $6.3 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinic...

    Details : Molecular engineering mRNA sequences with the VERSagile technology platform generates molecules optimized for improved protein secretion and allows for modulation of different therapeutic targets.

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    July 15, 2020

    Lead Product(s) : RNA based therapies

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Highest Development Status : Preclinical

    Sponsor : Undisclosed

    Deal Size : $6.3 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth